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Objective: To study systemic lupus erythematosus in a Brazilian population using the Amer-
ican  College of Rheumatology hematological classiﬁcation criteria and report associations
of  the disease with serological and clinical proﬁles.
Methods: This is a retrospective study of 460 systemic lupus erythematosus patients followed
in  a single rheumatologic center during the last 10 years. Hematological manifestations con-
sidered for this study were hemolysis, leukopenia, lymphocytopenia and thrombocytopenia.
Results: The cumulative prevalences of leukopenia, thrombocytopenia, lymphocytopenia
and  hemolytic anemia were 29.8%, 21.08%, 17.7% and 8.4%, respectively. A higher per-
centage of patients with hemolysis had anticardiolipin IgM (p-value = 0.002). Those with
leukopenia had more lymphopenia (p-value = 0.02), psychosis (p-value = 0.01), thrombocy-
topenia (p-value <0.0001) and anti-double stranded DNA antibodies (p-value = 0.03). Patients
with lymphopenia had more leukopenia (OR = 1.8; 95% CI = 1.01–3.29) and lupus antico-
agulant antibodies (OR = 2.2; 95% CI = 1.16–4.39) and those with thrombocytopenia had
more leukopenia (OR = 3.1; 95% CI = 1.82–5.44) and antiphospholipid syndrome (OR = 3.1; 95%
CI  = 1.28–7.87).
Conclusion: The most common hematological ﬁnding was leukopenia and the least com-
mon was hemolysis. Associations of low platelet count and hemolysis were found with
antiphospholipid syndrome and anticardiolipin IgM positivity, respectively. Leukopenia and
lymphocytopenia are correlated and leukopenia is more common in systemic lupus erythe-
matosus patients with psychosis, thrombocytopenia and anti-double stranded DNA.o Bra©  2015 Associac¸ã∗ Corresponding author at: Servic¸o de Reumatologia, Hospital Universitá
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Introduction
Systemic lupus erythematosus (SLE), a systemic autoimmune
disease most common in young females, has a very hetero-
geneous clinical proﬁle.1 The genetic background of patients
affects not only the prevalence of SLE but also the phenotype.2
Accordingly ethnic features favor the appearance of autoan-
tibodies and clinical clusters that deﬁne the subtypes of
the disease.3,4 These aspects highlight the need to know
lupus clusters as this awareness allows the clinician to pre-
dict a future manifestation from one already present. It also
highlights the need for local knowledge of disease behavior,
particularly in a population such as the Brazilian which is
highly mixed from the ethnic point of view.
The classical hematological manifestations in SLE are
hemolytic anemia, leukopenia, and thrombocytopenia; these
manifestations are part of the 1997 revised American College
Classiﬁcation Criteria for SLE5 as well as the new 2012 Sys-
temic Lupus International Collaborating Clinics Classiﬁcation
Criteria.6
According to previous works, thrombocytopenia has a
prevalence in the lupus population ranging from 7 to 30%.7–9
Although thrombocytopenia is not directly associated with
end organ damage, it deﬁnes a subgroup of patients with
higher morbidity and consequently has important prognostic
implications.10
Leukopenia is a typical feature of SLE and may occur as
a result of lymphopenia, neutropenia or both.11 Neutrope-
nia, which may be mediated by anti-neutrophil antibodies,
is common, with a prevalence in the order of 47%.11,12 The
prevalence of lymphopenia is variable, ranging from 20 to
81% and correlates with disease activity.12,13 Both T and B
lymphocytes are reduced while natural killer (NK) cells are
elevated.11,14 Although there are numerous reports of lym-
phocytotoxic antibodies,11,15 their signiﬁcance in this context
remains uncertain. Reduced surface expression of comple-
ment regulatory proteins such as CD55 and CD59 has also
been implicated in the pathogenesis of lupus lymphopenia,
as this deﬁciency will make cells susceptible to complement-
mediated lysis.11,16
Autoimmune hemolytic anemia (AIHA) is described in
7–15% of lupus patients and may occur together with immune
thrombocytopenia in the Evans syndrome.17,18 It is associated
with the presence of warm (predominantly) and cold anti-red
blood cell autoantibodies.17
The aim of the current study was to assess the prevalence
of hematological manifestations in a cohort of Brazilian lupus
patients as well as its associations with clinical and autoanti-
body proﬁles.
Methods
This is a retrospective study, approved by the local Research
Ethics Committee. The charts of 460 SLE patients seen over the
last 10 years in a single tertiary center were reviewed. To be
included in this study, patients had to comply with at least four
of the 1997 revised American College of Rheumatology classi-
ﬁcation criteria for SLE.5 Patients diagnosed before the age of 2 0 1 5;3  7(2):115–119
16 years and those with incomplete records were excluded.
Data on demographic, clinical and serological proﬁle were
obtained. The deﬁnition of all clinical ﬁndings followed those
of the ACR classiﬁcation criteria.5 The criteria were cumula-
tively considered when the patient had no known infections.
According to these criteria, hematological manifestations
were deﬁned as the presence of hemolytic anemia, leukopenia
deﬁned as less than 4 × 103 cells/mL on at least two occa-
sions, lymphopenia deﬁned as less than 1.5 × 103 cells/mL on
at least two occasions and thrombocytopenia deﬁned as less
than 100 × 103 cells/mL in the absence of an offending drug.5
Antiphospholipid syndrome (APS) was diagnosed according to
the 2006 modiﬁed APS criteria.19 The complete cell count was
performed using an automated analyzer (XE2100D, Sysmex)
and the white cell differential count was performed manually
using Giemsa stain.
Statistical  analysis
All obtained data were collected as frequencies in contin-
gency tables. The Kolmogorov–Smirnov test was used to study
data distribution. Groups of patients with one hematological
manifestation (hemolytic anemia, leukopenia or thrombocy-
topenia) were compared with those without this particular
manifestation in respect to other clinical manifestations and
their autoantibody proﬁle. Central tendency was expressed
as median and interquartile range (IQR) when numeric data
were nonparametric and mean and standard deviation (SD)
when parametric. Association studies were performed by
Fisher’s exact and chi-square tests for nominal data and with
Mann–Whitney and unpaired t-test for numerical data. All
variables that had signiﬁcance with a p-value <0.1 in univari-
ate analysis, were further studied using logistic regression to
assess independency. Statistical analyses were made using the
Medcalc software version 10.0, and signiﬁcance was set for an
alpha error of 5%.
Results
Analysis  of  the  sample
The sample was comprised of 93.5% females and 6.5% males
with ages ranging from 16 to 88 years and median disease
duration of 8 years. The clinic and serological proﬁles are listed
in Table 1.
Study  of  lupus  patients  with  hemolytic  anemia
The comparison data of patients with and without hemolytic
anemia (p-value <0.1) are shown in Table 2.
Association studies of hemolytic anemia with disease
duration, age at diagnosis, gender, photosensitivity, oral
ulcers, malar rash, discoid lesions, arthritis, glomerulonephri-
tis, seizures, psychosis, serositis, lymphopenia, anti-Ro/SS-A,
anti-La/SS-B, anti-ribonucleoprotein (anti-RNP), anti-double
stranded DNA (anti-dsDNA), rheumatoid factor and APS were
not signiﬁcant.
On further investigating variables with p-values <0.1 in
univariate analysis using a logistic regression model, only
rev bras hematol hemoter. 2 0
Table 1 – Clinical and serological proﬁle of lupus
patients.
n %
Photosensitivity 347/452 76.7
Oral ulcers 205/437 46.9
Malar rash 230/441 52. 1
Discoid lesions 57/441 15.1
Arthritis 281/458 61.3
Glomerulonephritis 183/457 40.0
Seizures 48/457 10.5
Psychosis 23/455 5.0
Serositis 81/457 17.7
Leukopenia 136/455 29.8
Lymphopenia 80/450 17.7
Hemolytic anemia 39/460 8.4
Thrombocytopenia 97/460 21.08
Anti Ro/SS-A 161/441 36.5
Anti La/SS-B 80/440 18.1
Anti RNP 110/421 26.1
Anti SM 87/434 20.0
Anti-dsDNA 150/444 33.7
Anticardiolipin IgG 54/443 12.1
Anticardiolipin IgM 53/443 11.9
Lupus anticoagulant 59/407 14.4
Rheumatoid factor 95/411 23.1
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Sultan et al., studying 305 lupus patients from the UnitedAntiphospholipid syndrome 33/439 7.5
nticardiolipin IgM remained signiﬁcant [p-value = 0.002; OR
.1; 95% conﬁdence interval (CI) = 1.7–14.9].
ssociation  studies  with  leukopenia
ata of patients with and without leukopenia (p-value <0.1)
re listed in Table 3. Comparisons of age, disease duration, age
t diagnosis, gender, photosensitivity, oral ulcers, malar rash,
iscoid lesions, arthritis, glomerulonephritis, serositis, pres-
nce of anti-Ro/SS-A; Anti-La/SS-B, anti-RNP, anticardiolipin
gG and IgM, rheumatoid factor and APS were not signiﬁcant.
On including the variables with a p-value <0.1 in the
nivariate analysis in a logistic regression model, lymphope-
ia (p-value = 0.02; OR = 1.8; 95% CI = 1.06–3.15), psychosis
p-value = 0.01; OR = 3.1; 95% CI = 1.22–8.03); thrombocytopenia
p-value <0.0001; OR = 3.2; 95% CI = 1.93–5.33); and anti-dsDNA
p-value = 0.03; OR = 1.6; 95% CI = 1.02–2.54) were indepen-
ently associated with leukopenia.
Table 2 – Association studies of demographic, clinical and serol
With hemolytic anemia
n = 39
Without h
Age years – median (IQR) 35.0 (23.0–47.0) 40.0 (
Leukopenia – n (%) 17/39 (43.5) 119/4
Thrombocytopenia – n (%) 14/31 (35.8) 83/41
Anti-SM – n (%) 10/36 (27.7) 77/39
Anticardiolipin IgG – n (%) 10/38 (26.3) 44/40
Anticardiolipin IgM – n (%) 14/38 (36.8) 39/40
Lupus anticoagulant – n (%) 12/34 (35.2) 47/37
IQR: interquartile range; OR: odds ratio; 95% CI: 95% conﬁdence interval. 1 5;3  7(2):115–119 117
Association  studies  of  thrombocytopenia
Association studies of thrombocytopenia are shown in
Table 4. Comparative analysis of associations with age,
disease duration, age at diagnosis, gender, oral ulcers,
malar rash, discoid lesions, glomerulonephritis, psychosis,
serositis, anti-Ro/SS-A, anti-La/SS-B, anti-RNP, anti-SM,
anti-dsDNA and rheumatoid factor were found to be
non-signiﬁcant.
When the variables with p-values <0.1 in univariate
analysis were assessed using logistic regression, arthritis
remained inversely associated to thrombocytopenia (OR = 0.3;
95% CI = 0.20–0.61) and leukopenia (OR = 3.1; 95% CI = 1.82–5.44)
and APS (OR = 3.1; 95% CI = 1.28–7.87) were associated to
thrombocytopenia.
Association  studies  of  lymphocytopenia
Associations of variables with lymphocytopenia are shown in
Table 5. Analysis of disease duration, gender, photosensiti-
vity, oral ulcers, malar rash, discoid lesions, arthritis, seizures,
psychosis, serositis, hemolytic anemia, anti-Ro, anti-dsDNA,
anticardiolipin IgG and IgM and rheumatoid factor were non-
signiﬁcant.
In the logistic regression study of variables with p-values
<0.1 in the univariate analysis, only leukopenia (OR = 1.8;
95% CI = 1.01–3.29) and lupus anticoagulant (OR = 2.2; 95%
CI = 1.16–4.39) remained independently signiﬁcant.
Discussion
Hematological ﬁndings in lupus patients are very common
and may be the presenting feature of the disease. In the
current study hemolytic anemia was the least common
manifestation (8%) followed by lymphopenia (18%), thrombo-
cytopenia (21%) and leukopenia (30%).
There was an association between hemolytic anemia and
anticardiolipin IgM antibodies; this association has been
described in other studies. Lang et al.20 described asso-
ciations with both anticardiolipin IgG and IgM antibodies.
18Kingdom, found an association with anticardiolipin IgG anti-
bodies but Deleze et al.21 studying Spanish lupus patients and
Cervera et al.8 analyzing a Mexican sample reported strong
ogical variables of lupus patients with hemolytic anemia.
emolytic anemia
n = 421
p-Value OR 95% CI
30.0–49.0) 0.06
16 (28.6) 0.0506 1.9 0.9–3.7
6 (19.9) 0.02 2.2 1.1–4.5
8 (19.3) <0.0001 5.4 2.6–1.4
5 (10.8) <0.0001 5.8 3.0–11.2
4 (9.6) <0.0001 5.4 2.6–11.4
3 (12.6) 0.001 3.7 1.7–8.1
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Table 3 – Comparison of lupus patients with (n = 136) and without (n = 319) leukopenia.
With leukopenia
n  (%)
Without leukopenia
n (%)
p-Value OR 95% CI
Seizures 20/136 (14.7) 28/316 (8.8) 0.06
Psychosis 14/136 (10.2) 9/317 (2.8) 0.0009 3.9 1.6–9.3
Lymphopenia 34/133 (25.5) 46/315 (14.6) 0.005 2.00 1.21–3.31
Hemolytic anemia 17/135 (12.5) 22/319 (6.8) 0.04 1.9 0.99–3.7
Thrombocytopenia 51/136 (37.5) 46/317 (14.5) <0.0001 3.5 2.2–5.6
Anti-dsDNA 55/134 (41.0) 95/307 (30.9) 0.03 1.55 1.02–2.36
Lupus anticoagulant 27/123 (21.9) 32/283 (11.3) 0.005 2.20 1.25–3.87
OR: odds ratio; 95% CI: 95% conﬁdence interval.
Table 4 – Comparison of lupus patients with (n = 97) and without (n = 363) thrombocytopenia.
With TCP
n (%)
Without TCP
n  (%)
p-Value OR 95% CI
Photosensitivity 67/96 (69.7) 268/356 (75.2) <0.0001 3.2 2.02–5.18
Arthritis 45/97 (46.3) 221/361 (61.2) 0.008 0.54 0.34–0.86
Seizures 14/96 (14.5) 30/361 (8.3) 0.06
Hemolytic anemia 14/96 (14.5) 20/361 (5.5) 0.002 2.9 1.41–6.00
Lymphopenia 23/94 (24.4) 54/356 (15.1) 0.03 1.8 1.04–3.14
Leukopenia 51/97 (52.5) 82/358 (22.9) <0.0001 3.7 2.33–5.96
Anticardiolipin IgG 18/95 (18.9) 34/348 (9.7) 0.01 2.1 1.15–4.02
Anticardiolipin IgM 17/95 (17.8) 34/347 (9.7) 0.01 2.1 1.15–4.02
Lupus anticoagulant 21/89 (23.9) 37/318 (11.6) 0.004 2.3 1.29–4.26
Antiphospholipid syndrome 16/94 (17.02) 17/345 (4.9) <0.0001 3.9 1.91–8.18
val.TCP: thrombocytopenia; OR: odds ratio; 95% CI: 95% conﬁdence inter
associations with anticardiolipin IgM antibodies similar to the
current study.
Leukopenia was the most common hematological ﬁnd-
ing in this study appearing in almost one in three of the
patients. The importance of this ﬁnding is highlighted when
one notes that infections are a leading cause of death in
SLE patients.22 Bacterial infections are the most common,
followed by viral and fungal infections.22 In this sample,
leukopenia was associated with lymphopenia, psychosis,
thrombocytopenia and anti-dsDNA. The correlation between
this ﬁnding, lymphopenia and ds-DNA has been reported
by others.17 A low lymphocyte count is found to be inde-
pendent of (although contributory to) leukopenia17 and has
been associated, in the literature, to higher lupus activity,23
Table 5 – Comparison of lupus patients with (n = 80) and withou
With lymphopenia
n  (%)
Without
Age (years; median, IQR) 35.0 (27.0–44.5) 41.0 (
Age at diagnosis (years; median, IQR) 30.0 (22.0–33.0) 26.0 (
Glomerulonephritis – n (%) 45/80 (56.2) 136/3
Thrombocytopenia – n (%) 23/79 (29.1) 71/37
Leukopenia – n (%) 34/80 (42.5) 99/36
Anti-La – n (%) 20/76 (26.3) 59/35
Anti-RNP – n (%) 31/73 (42.4) 77/24
Anti-SM – n (%) 25/75 (33.3) 60/35
Lupus anticoagulant – n (%) 15/71 (21.1) 43/33
Antiphospholipid syndrome – n (%) 12/75 (16.0) 21/35
IQR: interquartile range; OR: odds ratio; 95% CI: 95% conﬁdence interval.more  severe acral damage,23 and some clinical disease char-
acteristics such as neurologic involvement.17 In the current
sample, although lymphopenia was found to be associated
with glomerulonephritis, thrombocytopenia, anti-RNP, anti-
SM,  APS, lupus anticoagulant and leukopenia, only the last two
remained signiﬁcant after logistic regression. Lupus disease
activity and cumulative damage were not studied.
SLE thrombocytopenia results from disease activity or from
suppression of the bone marrow by an immunosuppressant.24
Autoantibodies against platelets, against thrombopoietin and
bone marrow abnormalities have been detected in these
patients.24 Although antibodies against platelets are common
among thrombocytopenic patients they are not always linked
to low platelet counts.24 Furthermore, anti-thrombopoietin
t (n = 370) lymphopenia.
 lymphopenia
n (%)
p-Value OR 95% CI
29.5–49.0) 0.004
19.0–35.7) 0.01
69 (36.8) 0.001 2.2 1.35–3.59
0 (19.1) 0.04 1.7 0.99–2.99
9 (26.9) 0.005 2.0 1.21–3.31
5 (16.6) 0.04 2.0 1.50–4.32
3 (22.4) 0.0004 2.5 1.21–3.31
1 (17.0) 0.0014 3.0 1.42–6.50
0 (13.0) 0.07
7 (5.8) 0.002 2.2 1.35–3.59
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utoantibodies are considered to have a weak effect on platelet
ounts.24 In the current study positive associations were
ound for thrombocytopenia with APS and with leukope-
ia. The association between APS and thrombocytopenia is
ell known not only in lupus but in other autoimmune
hrombocytopenias.17
onclusion
he most common hematological abnormality of the SLE
lassiﬁcation criteria in a cohort of Brazilian SLE patients
as leukopenia followed by thrombocytopenia, lymphopenia
nd hemolytic anemia. Low platelet counts and hemolysis
ere associated to APS and anticardiolipin IgM, respec-
ively. Leukopenia and lymphocytopenia are correlated and
eukopenia is more  common in SLE patients with psychosis,
hrombocytopenia and anti-dsDNA.
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